about
Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin ligaseGetting specificity from simplicity in putative proteins from the prebiotic EarthN-Terminal Helix-Cap in α-Helix 2 Modulates β-State Misfolding in Rabbit and Hamster Prion ProteinsStructural and functional characterization of KEOPS dimerization by Pcc1 and its role in t6A biosynthesisBinding of elongin A or a von Hippel-Lindau peptide stabilizes the structure of yeast elongin CStability of alpha-helicesDenaturational stress induces formation of zinc-deficient monomers of Cu,Zn superoxide dismutase: implications for pathogenesis in amyotrophic lateral sclerosis.Alternate routes to conformational specificity in a Greek key beta barrel protein.Equilibrium folding intermediates of a Greek key beta-barrel protein.Progress in transthyretin fibrillogenesis research strengthens the amyloid hypothesis.A prion protein epitope selective for the pathologically misfolded conformation.Cell surface binding and internalization of aβ modulated by degree of aggregationAβ behavior on neuronal membranes: aggregation and toxicities.Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death.Electrostatic Repulsion Governs TDP-43 C-terminal Domain AggregationDetermining composition of micron-scale protein deposits in neurodegenerative disease by spatially targeted optical microproteomics.Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretinCorrigendum: Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidosesStructural factors underlying the species barrier and susceptibility to infection in prion disease.Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis.Binding of TDP-43 to the 3'UTR of its cognate mRNA enhances its solubility.Probing Alzheimer amyloid peptide aggregation using a cell-free fluorescent protein refolding method."Structural characterization of the minimal segment of TDP-43 competent for aggregation".Wild-type Cu/Zn superoxide dismutase stabilizes mutant variants by heterodimerization.Interplay of buried histidine protonation and protein stability in prion misfolding.Phase to Phase with TDP-43.Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers.Two distinct conformations of Abeta aggregates on the surface of living PC12 cells.Variants of DsRed fluorescent protein: Development of a copper sensor.Helix propensities of the amino acids measured in alanine-based peptides without helix-stabilizing side-chain interactions.Nonpolar contributions to conformational specificity in assemblies of designed short helical peptides.Calexcitin B is a new member of the sarcoplasmic calcium-binding protein family.All or none fibrillogenesis of a prion peptide.Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH.Analyzing complicated protein folding kinetics rapidly by analytical Laplace inversion using a Tikhonov regularization variant.Conformational coupling of Mg2+ and Ca2+ on the three-state folding of calexcitin B.Determination of free energies of N-capping in alpha-helices by modification of the Lifson-Roig helix-coil therapy to include N- and C-capping.
P50
Q24336527-40823BC9-8E29-480B-A4D7-EB16B4B30F47Q27648142-0A55CC75-0B75-4B75-B469-01E4421FBF1BQ27678150-C23291DA-59BC-4017-AFEA-009625894B4CQ27710383-FCB7155B-8E7E-46B3-BF7E-33675118EF59Q27933200-B1705DBC-77DC-4F3B-A7F2-A3DD9377C92EQ28302560-65C7BB3E-D038-4433-AC14-AA381982B7BEQ30157535-4F635C6D-B59F-42F5-87B1-48FDC4631E75Q30167960-50396CA4-A1D6-4649-BB50-7177F940C14FQ30176227-C50BF41C-26F5-49EC-B26C-C8711F985649Q33952579-E867F493-88D7-45B9-B2F1-1243C86EFAAEQ34201802-B745DD2C-891B-4FDA-A3A9-DA5144B8577FQ34572746-101B4084-CD5C-445C-BBCC-5CDC7C190176Q35094356-B855893F-BDBF-4751-BE1B-7632E971EF22Q35746425-9EAB3B0A-FFEE-47D3-9D16-844CB0BAC5A7Q35994644-0FB336D7-4060-4F99-9971-268939D51035Q36242304-DEE88F2A-9FED-4E8A-A10E-44156D79E6EFQ36845920-4CA6EFFC-411A-44C0-92FA-02EA674F222CQ36981504-06BE4D39-8461-4C8F-9088-8C5FFDC6C000Q36991287-CEF7B72F-E83A-4FB5-B27D-227EAE042B81Q37746968-FC84F0BB-1786-43D5-B2AF-902CE23F6480Q38091029-896563D5-E3D7-466E-8DD7-943F13400227Q38304593-674542F2-32A4-425F-8903-EE02A4BE1621Q38350307-8234B75F-CF2B-4795-A04D-001345BD213AQ38450952-5B1A4482-ECFD-4226-BBE6-9DBD6ED7A0C1Q38452272-6DB90383-011C-4445-8646-8AC898E60561Q38837529-E136CEE2-0642-4506-A513-4323D6A5F882Q39098675-9E4A6F15-E924-45D7-9BC4-0138819D4AA5Q39141550-5B8502E0-CC2D-41A2-8901-D354ED54EBD1Q39745856-41F5AD4C-CCB1-4AFC-8616-04DCB450114DQ40984233-13BDEBB9-EC29-4158-8192-7C08F03B1D78Q42065112-A9A0373D-DA2C-4D1A-BE0C-5D385CAC2FACQ42103470-766E1EE4-0EE9-40B4-8ED4-8AF901C63C3AQ42244726-BA8C0964-216F-4857-80BD-EC15B560DCBCQ42847616-619D4AFE-E4F2-44AC-93E3-AE1F3F5701B3Q43578136-19C14966-FDCC-42C7-8108-D71C55C67BE8Q43739325-FD2032B6-7EE7-45A4-820E-97A473619D11Q44266485-0303961D-BE1E-4A24-BFF4-DA3511AC2214Q44297064-B4B4ED1B-92BA-461D-9DA7-936064A2D583Q44430467-CCFE7698-CB4C-47FB-B1FD-D85A7C1438E5Q44705720-C21F4F31-FD92-4903-AE7D-E7CC9911DC69
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Avi Chakrabartty
@ast
Avi Chakrabartty
@en
Avi Chakrabartty
@es
Avi Chakrabartty
@nl
type
label
Avi Chakrabartty
@ast
Avi Chakrabartty
@en
Avi Chakrabartty
@es
Avi Chakrabartty
@nl
prefLabel
Avi Chakrabartty
@ast
Avi Chakrabartty
@en
Avi Chakrabartty
@es
Avi Chakrabartty
@nl
P106
P31
P496
0000-0001-7002-8381